Kither Biotech Doses First Patients in KIT2014 COPD Trial
TURIN, Italy — September 29, 2026 Kither Biotech Pty Ltd and Kither Biotech Srl announced that the first patients...
Semaglutide
Advertisement
Caspian Unveils KO-7246 Preclinical Diabetes Data at EASD
SAN DIEGO — September 29, 2026 Caspian Therapeutics and Kura Oncology announced new preclinical data for KO-7246, an investigational,...
Artelo Files Patent for ART27.13 in Obesity
SOLANA BEACH, Calif. — September 23, 2026 Artelo Biosciences announced that it has filed a new provisional patent application...
Novo Nordisk Reports Positive Phase 3 CagriSema Resultsx
Bagsværd, Denmark, September 21, 2026 Novo Nordisk has announced topline results from two Phase 3 trials evaluating CagriSema, an...
Novo Nordisk Reports Positive STEP Young Phase 3 Data
Bagsværd, Denmark — September 7, 2026 Novo Nordisk announced positive first results from the STEP Young Phase 3 trial,...
Advertisements
Biomea Fusion Doses First Patient in Obesity OPAL Study
SAN CARLOS, Calif., August 13, 2026 Biomea Fusion, Inc. announced that the first participant has been dosed in a...
Aurisco Pharmaceutical Passes USFDA Inspection for Oligos
Shanghai, China, August 12, 2026 Aurisco Pharmaceutical announced that its manufacturing site in Yangzhou, China, has successfully passed a...
Veru Advances PLATEAU Trial with Full Enrollment
Miami, Florida, August 10, 2026 Veru Inc. has announced full enrollment of 239 patients in its Phase 2b PLATEAU...
Novo Nordisk Wins Dutch Injunction Over Semaglutide Spray
Bagsværd, Denmark, August 5, 2026 Novo Nordisk has secured a significant legal victory after the District Court of The...
Antag Therapeutics Doses First Patient in Phase 2a Trial of AT7687
COPENHAGEN, Denmark, July 28, 2026 Antag Therapeutics announced that the first patient has been dosed in its Phase 2a...
Advertisement
